Af­ter a rush of im­ports in­to the US in March as phar­ma com­pa­nies sought to get ahead of the Trump ad­min­is­tra­tion’s tar­iffs, trad­ing pat­terns have fall­en back to nor­mal, ac­cord­ing to US gov­ern­ment da­ta re­leased this week.

In March, phar­ma im­ports in­to the US reached $50.42 bil­lion, more than dou­ble their usu­al rate. The surge came af­ter Trump re­port­ed­ly warned phar­ma CEOs that he planned ex­ten­sive tar­iffs on the in­dus­try to push them to re­lo­cate man­u­fac­tur­ing to the US.

A source who works at a health­care lo­gis­tics provider said that the March spike had been dri­ven by tar­iff-re­lat­ed stock­pil­ing and has sub­se­quent­ly sta­bi­lized af­ter a rush of ship­ments. With US tar­iff pol­i­cy now in flux and some­times chang­ing from day to day, the source said that drug com­pa­nies had large­ly gone back to reg­u­lar ship­ping op­er­a­tions.

The Eu­ro­pean Med­i­cines Agency said Fri­day that the prod­uct in­for­ma­tion for No­vo Nordisk’s Ozem­pic and We­govy should be up­dat­ed to list a se­ri­ous eye con­di­tion as a “very rare” side ef­fect.

A flur­ry of stud­ies have ex­am­ined a pos­si­ble as­so­ci­a­tion be­tween eye-re­lat­ed con­di­tions and the pop­u­lar GLP-1 drugs. The EMA’s safe­ty com­mit­tee con­clud­ed this week that non-ar­terit­ic an­te­ri­or is­chemic op­tic neu­ropa­thy (NAION) “is a very rare side ef­fect of semaglu­tide (mean­ing it may af­fect up to 1 in 10,000 peo­ple tak­ing semaglu­tide).” NAION can cause the sud­den loss of vi­sion in one eye.

The Phar­ma­covig­i­lance Risk As­sess­ment Com­mit­tee, or PRAC, said it came to the con­clu­sion af­ter re­view­ing da­ta “from non-clin­i­cal stud­ies, clin­i­cal tri­als, post-mar­ket­ing sur­veil­lance and the med­ical lit­er­a­ture.”

Oma­da Health's stock jumped 21% as it start­ed trad­ing in a strong sig­nal for the sec­ond dig­i­tal health com­pa­ny to break in­to the pub­lic mar­ket this year.

The vir­tu­al chron­ic care com­pa­ny's stock OM­DA opened at $23 a share on Fri­day, above the $19 per share price set on Thurs­day night. The price at the start of trad­ing gives Oma­da a mar­ket val­ue of about $1.3 bil­lion af­ter sell­ing 7.9 mil­lion shares in the ini­tial pub­lic of­fer­ing.

Oma­da’s de­but fol­lows the strong May IPO of fel­low San Fran­cis­co-based dig­i­tal health com­pa­ny Hinge Health. It’s a pos­i­tive sign for the in­dus­try, which is look­ing for an open­ing in the pub­lic mar­kets af­ter a chilly cou­ple of years that fol­lowed record ac­tiv­i­ty dur­ing the Covid-19 pan­dem­ic.

Al­though Sum­mit Ther­a­peu­tics didn’t present any da­ta at AS­CO's an­nu­al meet­ing, it still dom­i­nat­ed the con­ver­sa­tion at Mc­Cormick Place in Chica­go.

The com­pa­ny put out a press re­lease the same Fri­day morn­ing that the con­fer­ence start­ed in a games­man-like move, out­lin&sh